Compare FATE & VFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FATE | VFL |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.6M | 127.7M |
| IPO Year | 2013 | 1994 |
| Metric | FATE | VFL |
|---|---|---|
| Price | $1.18 | $10.12 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.10 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 32.1K |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,646,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.66 | $9.27 |
| 52 Week High | $1.94 | $10.50 |
| Indicator | FATE | VFL |
|---|---|---|
| Relative Strength Index (RSI) | 40.66 | 25.71 |
| Support Level | $0.96 | $9.99 |
| Resistance Level | $1.35 | $10.13 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 0.00 | 0.03 |
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Delaware Investments Natl Muni Income is a closed-end investment fund. The Fund's investment objective is to seek to provide current income exempt from regular federal income tax, consistent with the preservation of capital. The company's product portfolio includes Mutual funds, Exchange-traded funds, Private markets, and Closed-end funds.